Psilocybin-Assisted Therapy
From the Mazatec Ceremony to Breakthrough-Therapy Trials
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
Landmark trials at Johns Hopkins and NYU report large effect sizes for treatment-resistant depression and for existential distress in people with life-threatening illness, with patient-reported outcomes that exceed many conventional antidepressant trials and durability measured in months. The honest caveats are real: trials cannot be blinded, sample sizes are still modest, and long-term safety data are limited. The evidence is strong for what has been measured and incomplete on duration and scale.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| Treatment-resistant depression | 4 of 5 | Large effect sizes; FDA breakthrough-therapy interest. |
| End-of-life existential distress | 4 of 5 | Durable benefit in life-threatening illness. |
| Substance use disorders | 3 of 5 | Promising early trials; smaller and less mature. |
| Unsupervised or recreational use as therapy | 1 of 5 | The therapeutic model depends on preparation, support, and integration. |
What can go wrong
Psilocybin has low physiological toxicity but real psychological risk outside a supported setting: frightening experiences, lasting destabilization in vulnerable people, and danger for those with personal or family histories of psychosis or bipolar disorder. Cardiac caution applies. The clinical safety record depends on screening, preparation, a supported session, and integration; none of that is present in unsupervised use.
This is something to take to a clinician. The Atlas can tell you what is known about psilocybin-assisted therapy in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Psilocybin-assisted therapy compresses the whole Atlas into one entry: a thousand-year-old Indigenous healing tradition, a forty-year politically driven research ban, a present-day research frontier with unusually strong outcomes, and an unresolved question of cultural ownership. Mazatec healers used the mushrooms ceremonially long before Western science arrived in 1957, an arrival that harmed the curandera Maria Sabina and her community. The 1970 Schedule I listing then halted rigorous study for four decades. When research resumed at Johns Hopkins and NYU, it produced large, durable effects for treatment-resistant depression and end-of-life distress, alongside honest caveats about unblindable trials and limited long-term data. We grade the depression and end-of-life evidence at grade 4, document the suppression as historical fact, map the fast-moving regulatory picture across jurisdictions, and name the Mazatec origin first.
A mushroom medicine used in Mesoamerican healing for at least a thousand years, banned from research for forty, and now producing some of the strongest patient-reported outcomes in psychiatry.
How it works
Psilocybin is metabolized to psilocin, a 5-HT2A serotonin receptor agonist. It acutely increases neuroplasticity, reduces activity in the default mode network associated with rumination and rigid self-referential thinking, and increases global brain connectivity. In several trials the benefits of one to three guided sessions persist for weeks to months, suggesting a window of enhanced plasticity rather than a drug that must be taken continuously.
What people get wrong
Often saidPsilocybin therapy is just getting high in a clinic.
ActuallyThe clinical model is built on screening, preparation, a supported dosing session, and integration. The drug without that container is a different and riskier thing.
Often saidThe 1970 ban was a neutral safety decision.
ActuallyThe documented record, including statements by a Nixon official, ties the drug war to political targeting. The forty-year research gap reflects politics as much as pharmacology.
Who profits, and who pushes back
Roland Griffiths / Matthew Johnson (Johns Hopkins)
Report large, durable improvements in depression and end-of-life distress after one to three guided sessions.
FDA
Has granted breakthrough-therapy designation and priority vouchers while requiring further evidence on safety and durability.
Methodological skeptics
Caution that unblindable trials and expectancy effects complicate interpretation of the large effect sizes.
Indigenous and Mazatec advocates
Question commercialization that extracts the medicine from its originating community without benefit-sharing or acknowledgment.
Where the research comes from
Most of the published research on this comes from one place. 95% of it is from Mexico (Mazatec lineage). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Mexico (Mazatec lineage) | 95% |
| United States (Johns Hopkins, NYU) | 90% |
| Switzerland / Oregon / Australia | 70% |
How we got here
The lineage begins in Mesoamerica, not the laboratory. Mazatec healers in what is now Oaxaca, Mexico, have used psilocybin mushrooms, teonanacatl, in healing ceremonies for at least a thousand years. The curandera Maria Sabina (1894 to 1985) was a keeper of that tradition; her sharing of a ceremony with the American banker R. Gordon Wasson, published in LIFE magazine in 1957, brought Western attention that damaged her standing and her community. Only after that did Western pharmacology, at Sandoz and in the early-1960s Harvard Psilocybin Project, take up the compound, before prohibition shut the work down.
Ceremonial Mazatec use spans at least a millennium. Western pharmacology engaged it after 1957 (Sandoz synthesis, the early-1960s Harvard Psilocybin Project), before the 1970 Schedule I listing halted research. Johns Hopkins and NYU relaunched rigorous studies from around 2006, and from the late 2010s into the 2020s the field moved toward regulated access in several jurisdictions, accelerated by an April 2026 US executive order.
- ~1000 CE and earlierMazatec and Mesoamerican ceremonial use
- 1957Wasson's LIFE article brings Western attention; harm to Maria Sabina's community
- 1960-1963Harvard Psilocybin Project
- 1970US Schedule I listing halts research
- ~2006Johns Hopkins relaunches rigorous study
- 2023-2026Oregon, Australia access; US executive order and priority vouchers
How it is understood
In its originating tradition psilocybin is a sacrament administered by a trained healer within a structured nighttime ceremony of song and prayer, not a recreational drug or a pill. Contemporary clinical models echo this in their emphasis on preparation, a supported dosing session, and integration, even as they strip the religious frame.
Where scholars disagree
The dispute is not whether psilocybin therapy helps but how much of the effect is the drug versus the context, and how to trust trials in which blinding is impossible. Participants almost always know whether they received an active psychedelic, so expectancy, set, and setting plausibly contribute to the large effects. Researchers also debate the optimal model (drug plus structured therapy versus drug alone) and the still-limited long-term safety data.
Johns Hopkins and NYU trial groups
Guided psilocybin sessions produce large, durable reductions in treatment-resistant depression and end-of-life distress.
What it rests onRandomized trials with large effect sizes and months-long durability of response.
Methodological skeptics
Unblindable trials and powerful expectancy effects inflate apparent efficacy; the active-drug-versus-context question is unresolved.
What it rests onFunctional unblinding in psychedelic trials and the known size of expectancy effects in subjective outcomes.
This disagreement is live. It has not settled.
At a glance
- Indigenous use
- Mazatec ceremony, 1,000-plus years
- Western exposure
- Wasson in LIFE, 1957
- Research ban
- US Schedule I, 1970 to late 1990s
- Mechanism
- 5-HT2A agonism; default-mode-network downshift
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Psilocybin-Assisted Therapy. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.